The Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster University is a world-leading centre of transdisciplinary infectious disease research.
Since its inception in 2007 through an unprecedented gift from Hamilton businessman Michael G. DeGroote, the IIDR has brought together a successful team of over 30 principal investigators and 2000 trainees, all of whom are committed to delivering new knowledge and solutions to some of the most pressing challenges in infectious disease. Our members span a variety of disciplines ranging from medicine and biochemistry to mathematics, anthropology, and engineering, among others. Through collaborative research that spans the lab and the clinic, our team is dedicated to finding new treatments and preventions to control infections that have devastating impacts on health.
McMaster University’s cutting-edge genomic, imaging, Biosafety Level 3 (BSL3) and animal facilities enable the IIDR’s fundamental and applied research initiatives. The IIDR’s core supporting infrastructure – the Centre for Microbial Chemical Biology – is a 7,000-square-foot laboratory that features six integrated labs, allowing chemical biology research to be conducted in one central location.
The breadth of research initiatives at the IIDR is large, reflecting the complexity of global challenges in infectious disease research and clinical practice. Further, the IIDR continually advances its research objectives to align with the evolving infectious disease landscape. Such initiatives fall into three general categories:
1) Microbial Research – Including fundamental research into the causation, detection and treatment antibiotic resistance, the discovery of new antibiotics and antibiotic alternatives, and the study of microbial physiology and microbial evolutionary biology;
2) Host-Pathogen Interaction Research – Including the study of immunity and pathogenesis, microbiome research, and the mathematical modelling of infectious disease from the level of molecules to populations;
3) The Discovery and Development of New Technologies – Including novel inventions and innovations in drug discovery, diagnostics, vaccinology, and materials science.
Over the last decade, the IIDR has made significant contributions within these fields – our members have published their findings in top scientific journals, invented novel technologies, and developed multiple spinout companies in the areas of drug discovery, genomics, and bioinformatics. As such, the IIDR has built an international reputation as an institute synonymous with commitment and innovation.
The David Braley Centre for Antibiotic Discovery
Public health agencies across the globe agree that antimicrobial resistance is one of the most significant threats to modern medicine in the 21st century. In 2019, the David Braley Centre for Antibiotic Discovery was established with the vision of successfully addressing this crisis. Members of the DBCAD are committed to discovering and developing new resources, treatments, diagnostics, and clinical strategies through innovation in antimicrobial resistance research and antibiotic discovery.
The Canadian Anti-infectives Network
In 2016, the IIDR spearheading the launch of the Canadian Anti-infective Innovation Network (CAIN) – a consortium of over 80 Canadian leaders, researchers, clinicians, and policymakers from various universities, companies, governments, and not-for-profit organizations all committed to addressing the increasing global threat of antimicrobial resistance (AMR). CAIN members span human and animal health sectors, bring the breadth and expertise needed to harness the potential in the field.
The Centre for Chemical Microbial Biology (CMCB)
The Centre for Chemical Microbial Biology (CMCB) is an open-access facility associated with the David Braley Centre for Antibiotic Discovery and Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. The facility features six integrated labs that provide research support, hands-on training, and services in chemistry and biology.